33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors
    Meeting Abstract

    Autio, K. A.; Arkenau, H. T.; O'Neil, B. H.; Bendell, J. C.; El-Khoueiry, A.; Strauss, J.; Weise, A.; Uboha, N. V.; Rizvi, N. A.; Zheng, B.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC
    Meeting Abstract

    Arbour, K. C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Bernal, G. M.; Chaft, J. E.; Ferrara, R.; Lai, W. C. V.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E)
    Meeting Abstract

    Armstrong, A. J.; Halabi, S.; Luo, J.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Healy, P.; Anand, M.; Rothwell, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors
    Meeting Abstract

    Aguilar, E. J.; Rizvi, H.; Kravets, S.; Lydon, C. A.; Adeni, A. E.; Subegdjo, S.; Hellmann, M. D.; Awad, M. M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • E-cigarette use among patients of smoking-related cancers in the United States
    Meeting Abstract

    Akinboro, O.; Elias, R.; Nwabudike, S. M.; Balasire, O.; Ostroff, J. S.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Survival outcome of breast cancer (BC) patients presenting with recurrent and de novo isolated contralateral lymph node metastases (CLNM)
    Meeting Abstract

    Al-Awadhi, A.; Lei, X.; Sanford, R. A.; Valero, V.; Giordano, S. H.; Chavez-MacGregor, M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A comparative safety analysis for durvalumab in patients with locally advanced, unresectable NSCLC: PACIFIC versus pooled durvalumab monotherapy studies
    Meeting Abstract

    Antonia, S. J.; Hellmann, M. D.; Dennis, P. A.; Melillo, G.; Abdullah, S. E.; Lloyd, A.; Rizvi, N. A.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • High frequency mismatch repair (MMR) pathway mutations in adrenocortical carcinoma: Indication for routine MMR-deficiency (MMR-D) testing
    Meeting Abstract

    Akala, O. O.; Kelly, V.; Strong, V. E.; Gopalan, A.; Reidy, D. L.; Raj, N. P.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors
    Meeting Abstract

    Ahnert, J. R.; Taylor, M. H.; O'Reilly, E. M.; Zhang, J.; Doebele, R. C.; Ben, Y.; Sharp, L. L.; Boyle, W. J.; Chang, C.; Frey, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study
    Meeting Abstract

    Aghajanian, C.; Coleman, R. L.; Oza, A. M.; Lorusso, D.; Oaknin, A.; Dean, A. P.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save